Emmaus Life Sciences, Inc.
No enriched coverage for $EMMA in the last 7 days.
Emmaus Life Sciences, Inc. (EMMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, August 14, 2026 - Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial conditi
In the last 30 days, EMMA insiders filed 4 SEC Form 4 transactions — 4 purchases ($15K) and no sales. The most active reporter was LEE WILLIS C, CEO, with 4 filings.
Revenue and operating income improved materially due to upfront license revenue recognition, while cash remains modest.
AlphAI scores every news story that mentions EMMA with an AI model for sentiment and relevance, and aggregates insider trades from Emmaus Life Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Emmaus Life Sciences, Inc. (EMMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, August 14, 2026 - Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial conditi
6 min read